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Acute lymphoblastic leukemia (ALL) accounts for∼25% of pediatric malignancies. Of interest, the incidence of
ALL is observed∼20% higher in males relative to females. The mechanism behind the phenomenon of sex-spe-
cific differences is presently not understood. Employing genome-wide genetic aberration screening in 19 ALL
samples, one of the most recurrent lesions identified was monoallelic deletion of the 5′ region of SLX4IP. We
characterized this deletion by conventional molecular genetic techniques and analyzed its interrelationships
with biological and clinical characteristics using specimens and data from 993 pediatric patients enrolled into
trial AIEOP-BFM ALL 2000. Deletion of SLX4IP was detected in ∼30% of patients. Breakpoints within SLX4IP
were defined to recurrent positions and revealed junctions with typical characteristics of illegitimate V(D)J-
mediated recombination. In initial and validation analyses, SLX4IP deletions were significantly associated
with male gender and ETV6/RUNX1-rearranged ALL (both overall P < 0.0001). For mechanistic validation, a
second recurrent deletion affecting TAL1 and caused by the same molecular mechanism was analyzed in
1149 T-cell ALL patients. Validating a differential role by sex of illegitimate V(D)J-mediated recombination at
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the TAL1 locus, 128 out of 1149 T-cell ALL samples bore a deletion and males were significantly more
often affected (P 5 0.002). The repeatedly detected association of SLX4IP deletion with male sex and the exten-
sion of the sex bias to deletion of theTAL1 locus suggest that differential illegitimate V(D)J-mediated recombin-
ation events at specific loci may contribute to the consistent observation of higher incidence rates of childhood
ALL in boys compared with girls.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common child-
hood malignancy (1–3). Despite intensive research efforts, the
causes of childhood ALL remain largely unknown. Sex bias—
characterized by a 20% higher incidence in males relative to
females—is consistently observed in childhood ALL (2–4).
In addition, male sex is associated with worse treatment response
and outcome (5,6). Therefore, a better understanding of this phe-
nomenon could directly enhance our understanding of disease
etiology and improve therapeutic approaches to ALL.
From a genetic perspective, ALL is characterized by recurrent
numeric and/or structural somatic aberrations (7). Hyperdiploidy
or the cryptic chromosomal translocation t(12;21)—leading to an
ETV6/RUNX1 gene fusion—are detectable in 20–25% of cases
each, making them the most common genetic subtypes of child-
hood ALL (7,8). Important for pathomechanistic insights, the mo-
lecular features associated with the breakpoints of structural
genetic aberrations in ALL are multifold and include, for
example, an open chromatin context during gene transcription,
Alu and other repeat sequences, or illegitimate V(D)J-mediated
recombination (7).
V(D)J recombination is a physiological process by which seg-
ments (variable (V), diversity (D), joining (J)) of immunoglobu-
lin (Ig) or T-cell receptor (TCR) genes are rearranged and lead to
great diversity of the Ig/TCR repertoire. This process is mediated
by lymphocyte-specific endonucleases (RAG1, RAG2) which
cut the regional V(D)J genes at flanking recombination signal
sequences (RSS) consisting of specific highly conserved hepta-
mer and nonamer sequences with an unconserved spacer (12 or
23 nucleotides) in-between (9,10). Subsequently, the coding
segments are joined using the classical non-homologous end-
joining (NHEJ) pathway. Paradoxically, RAG proteins can
recognize a variety of slightly modified RSS sequences increas-
ing the chance of erroneously targeting RSS-like sequences
(‘cryptic RSS’) elsewhere in the genome. Several chromosomal
translocations between Ig/TCR loci and proto-oncogenes as well
as deletions of non-antigen receptor loci in lymphoid malignan-
cies are thought to be generated by such illegitimate V(D)J-
mediated recombination events (11,12). Recently, interstitial
deletion of the B-cell translocation gene 1 (BTG1) in 9% of
precursor B-cell ALL has been attributed to this mechanism
(13). Also, subtypes of CDKN2A and IKZF1 deletions as well
as all TAL1 deletions have been associated with off-target
action of the RAG complex (12,14–16).
In the present study, we describe a highly frequent deletion in
SLX4IP—a gene encoding a currently uncharacterized DNA
repair-related protein—by illegitimate V(D)J-mediated recom-
bination (17). SLX4IP deletion has previously been reported in
childhood ALL, but at a far lower frequency (18,19). We correl-
ate this finding to demographic and clinical characteristics in a
large cohort of children with ALL and describe its specific asso-
ciation with ETV6/RUNX1-rearranged ALL and male sex.
RESULTS
In our initial screen for recurrent genetic aberrations in childhood
ALL employing comparative genomic hybridization (CGH) ana-
lysis, 5 out of 19 samples—making it one of the most common
observations—harbored a monoallelic deletion encompassing the
first two exons of the SLX4IP gene with tight breakpoint clustering
to a defined position (HG18, chromosome 20: 10 363 654–10
404 199 bp; Fig. 1A). Sequencing analysis in the five deletion-
positive samples revealed patient-specific breakpoints within only
a few nucleotides of each other—confirming site specificity of the
recombination event—and demonstrated near perfect matches to
5′ and 3′ heptamer sequences (consensus 5′-CACAGTG), non-
templated ‘N’ nucleotides and ‘nibbling away’ of nucleotides at
the junction points as hallmarks of illegitimate V(D)J-mediated re-
combination(Fig.1B–D)(11,12,14,16,20).NoconvincingAT-rich
nonamer sequences (consensus 5′-ACAAAAACC) were found at
12 or 23 nucleotides distance of the heptamers. As all five patients
displaying the SLX4IP deletion at initial diagnosis relapsed, we
nextanalyzedALLsamplesobtainedatdisease recurrenceformain-
tenance of aberrations during leukemic evolution and detected the
same patient-specific deletion breakpoints in all samples (Fig. 1D).
As the above analyses were performed on selected patients,
we next aimed at a reliable assessment of the SLX4IP deletion
frequency in a cohort of 512 patients enrolled into AIEOP-BFM
ALL 2000 (Cohort 1, Table 1, Supplementary Material, Fig. S1)
(5,6). Employing a PCR assay, the deletion could be detected in
164 children (32.0%). When analyzing the association of
SLX4IP deletion with clinical characteristics, the most signifi-
cant positive interrelationships were observed for male sex
(P , 0.001) and ETV6/RUNX1-rearranged ALL (P , 0.001)
(Table 1). In an analysis stratified byETV6/RUNX1 translocation
status, the male sex bias stayed significant in translocation posi-
tive (P, 0.001) as well as negative patients (P , 0.001)
(Tables 2 and 3). No association of SLX4IP deletion with treat-
ment outcome was detected (Supplementary Material, Fig. S2).
To validate the observed interrelationships, we next screened
an independent cohort of 232 patients with ETV6/RUNX1-
rearranged ALL from AIEOP-BFM ALL 2000 (Cohort 2) and
identified 145 (62.5%) deletion-positive samples. In these ana-
lyses, both the association of SLX4IP deletion with male sex
(P ¼ 0.049) and its high incidence in ETV6/RUNX1-rearranged
ALL could be confirmed (Table 3, Supplementary Material,
Table S1). In a second validation step, we screened 249 leukemic
ETV6/RUNX1-negative samples from AIEOP-BFM ALL 2000
patients enrolled in the years 2001 and 2002 (Cohort 3) and,
again, found a significant positive association of SLX4IP
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deletion status with male sex (P ¼ 0.029) (Table 3, Supplemen-
tary Material, Table S2).
To consolidate our findings on SLX4IP deletion characteris-
tics at the nucleotide level which were based on five samples
only, we continued by sequencing 38 additional leukemic
patient DNA samples and detected site-specific SLX4IP break-
point junctions with typical characteristics of illegitimate
V(D)J-mediated recombination in all specimens (Supplemen-
tary Material, Table S3). This suggests that—similar to T-cell
ALL with its high frequency of illegitimate V(D)J-mediated
recombination events—precursor B-cell ALL bears site-specific
recombination events with non-dispersed breakpoints in associ-
ation with cryptic RSS at a previously underestimated high fre-
quency (.25%). Of importance, 50% of samples exhibited
signs of oligoclonality, indicating that different SLX4IP-deleted
subclones existed in parallel.
Recently, it was demonstrated that subclones in ALL have
variegated genetics associated with a dynamic clonal architec-
ture in the lead-up to a diagnosis and in relapse (21). To charac-
terize the behavior of the SLX4IP deletion during leukemic
Figure 1. Deletion of the first two exons of SLX4IP on chromosome 20 in five ETV6/RUNX1-negative ALL samples. (A) Custom made NimbleGen fine-tiling
CGH-array illustrating a uniform deletion at diagnosis. (B) PCR product of the same samples showing the SLX4IP deletion at diagnosis and relapse. No PCR products
regardingSLX4IPdeletion are discovered in remission (germline). Patient samples are depicted in the following order: KY-3: lines 1, 6 and 11; KY-2: lines 2, 7 and 12;
KY-5: lines 3, 8 and 13; KY-1: lines 4, 9 and 14; KY-4: lines 5, 10 and 15. bp ¼ 100 base pair DNA ladder. L ¼ negative control. HPRT exons 7 and 8 were used as
positive control. (C) TheSLX4IPdeletion junction sequence is displayed and remains unchanged from diagnosis to relapse. Dotted lines illustrate breakpoints at the 5′
and 3′ end of the deletion and N-nucleotides are allocated in-between. (D) The SLX4IP deletion junction sequence at diagnosis and relapse is shown in alignment with
wild-type sequence. Signs of illegitimate V(D)J-mediated recombination are displayed. The pseudo-heptamer as part of the pseudo-RSS is depicted as black box. The
potential pseudo-nonamer sequence is underlined, separated either by a 12-RSS or 23-RSS.
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evolution, we extended our above described preliminary analyses
of initial diagnosisandrelapse samples toa total of22 pairs (Fig.1;
Supplementary Material, Table S4). The deletion was confirmed
at relapse in 21 paired samples by PCR. Sequence analysis
of the respective breakpoints showed the same monoclonal
sequences in nine patients indicating stability ofSLX4IPdeletions
during disease progression. The remaining samples either devel-
oped heterogeneity of SLX4IP breakpoints at relapse subsequent
to monoclonal sequences (n ¼ 1) or already showed an oligoclo-
nal pattern at initial diagnosis (n ¼ 11) (Supplementary Material,
Fig. S3). Backtracking of SLX4IP deletions to birth in seven
ETV6/RUNX1-positive patients using material derived from
Guthrie cards did not yield any positive results suggesting that de-
letion of SLX4IP is a secondary event occurring after birth (Sup-
plementary Material, Fig. S4). Although backtracking of
SLX4IP deletions may have been hampered by the sensitivity of
the detection method, a secondary nature of the deletions is sup-
ported by the observation that in monozygotic twins with ETV6/
RUNX1-positive ALL and identical translocation breakpoints,
the SLX4IP deletion was detectable in one diagnostic leukemic
sample only while the second twin was negative (Supplementary
Material, Fig. S5). None of 134 available matching bone marrow
remissionsamples fromCohort1exhibited theSLX4IPdeletionas
well as noneof 145 peripheral blood samples derivedfrom healthy
blood donors.
To gain information on functional consequences of SLX4IP
deletion, we next compared its expression in 60 diagnostic
ALL specimens carrying the deletion with 60 deletion-negative
samples (Supplementary Material, Table S5). We did not find
significant differences by SLX4IP deletion status (P ¼ 0.793),
but ETV6/RUNX1-positive samples demonstrated higher SLX4IP
expression compared with ETV6/RUNX1 negatives (Fig. 2,
P, 0.001). Next, we investigated a potential effect of SLX4IP de-
letion on the expression of neighboring genes (MKKS and JAG1,
Supplementary Material, Table S5 and S6) (22,23). While no dif-
ferential expression of the MKKS gene was seen (P ¼ 0.826),
patients carrying a SLX4IP deletion demonstrated significantly
higher expression of JAG1 (P, 0.001). Also here, we performed
stratified analysis by ETV6/RUNX1 status and observed signifi-
cantly higher expression of JAG1 in SLX4IP-deleted samples in
theETV6/RUNX1-negative subgroup (P ¼ 0.011), whereas posi-
tive patients demonstrated uniformly high JAG1 expression with
no discernable differences according to SLX4IP deletion status
(P ¼ 0.999) (Fig. 2).
Figure 1. Continued
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To find out whether an increased male susceptibility to illegit-
imate V(D)J-mediated recombination was restricted to the
SLX4IP locus or could be extended to other loci, we finally ana-
lyzed illegitimate V(D)J-mediated deletions of TAL1 in a cohort
1149 T-cell ALL patients from trials AIEOP-BFM ALL 2000
and ALL IC-BFM 2002 (Cohort 4). We were able to identify
128 (11.1%) TAL1-deleted patients with 110 (85.9%) out of
them being male. Similar to SLX4IP, this distribution resulted
in a significant positive association of TAL1 deletion status
with male sex (P ¼ 0.002) (Table 3). Thus, an increased male
susceptibility to the event of illegitimate V(D)J-mediated
recombination could also be observed at the TAL1 locus. In add-
itional analyses employing multiplex ligation-dependent probe
amplification (MPLA) data on IKZF1 and BTG1 deletions
which were previously described as being V(D)J-mediated we
could not detect a sex-biased distribution of deletions (Supple-
mentary Material, Table S7) (13,24,25).
DISCUSSION
Here, we describe a site-specific deletion within the 5′ region of
the SLX4IP locus in 30% of childhood ALL in general and
.60% of ETV6/RUNX1-rearranged ALL, making the deletion
of SLX4IP one of the most common aberrations in childhood
ALL described so far. As SLX4IP deletions were previously
only described at far lower frequencies in array-based genome-
wide analyses of representative large cohorts (18,19), our obser-
vation of SLX4IP deletion at a much higher percentage by PCR
analysis implies that the subclonal architecture of ALL in asso-
ciation with methodological sensitivity thresholds introduces
bias in frequency estimates of genetic aberrations by convention-
al SNP array or CGH analyses. Most likely, a larger proportion of
SLX4IP deletions detected in our study occurred at later stages of
leukemic evolution secondary to ETV6/RUNX1 rearrangements
and were, therefore, only present in a fraction of leukemic cells.
These subclonal levels would have been missed by array techni-
ques requiring presence of a lesion in a majority of analyzed cells
for reliable detection. The particular sensitivity of the SLX4IP
locus to secondary recombination events is further exemplified
by the fact that breakpoint sequencing revealed oligoclonality
in nearly half of the SLX4IP deletion-positive samples analyzed
at initial diagnosis of ALL.
The described deletion in the 5′ region of SLX4IP differs from
other recurrently detectable genetic aberrations of comparable
frequencies in childhood ALL in the way that it occurs in a site-
specific fashion and consistently demonstrates features of a
single causal mechanism—illegitimate V(D)J-mediated recom-
bination. The repeatedly detected association of SLX4IP dele-
tion with male sex in our study and the extension of the sex
bias to deletion of the TAL1 locus imply that differential suscep-
tibility by sex to illegitimate V(D)J-mediated recombination at
specific loci may contribute to the consistent observation of
higher incidence rates of childhood ALL in boys compared
with girls. We were not able to extend our findings to two add-
itional loci recurrently displaying features of illegitimate
V(D)J-mediated recombination at their breakpoints—IKZF1
and BTG1 (13,14). This suggests that our thoroughly validated
observation of sex-specific acquisition of SLX4IP and TAL1
deletions by illegitimate V(D)J-mediated recombination
cannot be generalized to all loci demonstrating susceptibility
to illegitimate V(D)J-mediated recombination. The mechanism
underlying these locus-specific findings remains to be clarified.
Potential explanations could include locus-specific differences,
variation in sex-specific susceptibility to illegitimate V(D)J-
mediated recombination for biological subgroups of ALL, or
SLX4IP and TAL1 deletions occurring with equal frequencies
in males and females, but underlying sex-specific differences
in selection processes during leukemia development.
Sex differences exist in a variety of diseases including, besides
others, autoimmune disorders and infectious diseases, and are
Table 1. Clinical characteristics of 512 patients with ALL from trial
AIEOP-BFM ALL 2000 (Cohort 1) by SLX4IP deletion status
Patients positive for
SLX4IP deletion
(n ¼ 164) n (%)
Patients negative for
SLX4IP deletion
(n ¼ 348) n (%)
P-valued
Gender
Male 124 (75.6) 181 (52.0)
Female 40 (24.4) 167 (48.0) ,0.001
Age at diagnosis (years)
,1 0 (0.0) 0 (0.0)
1–,5 79 (48.2) 161 (46.3)
5–,10 49 (29.9) 90 (25.9)
10–,15 23 (14.0) 73 (21.0)
≥15 13 (7.9) 24 (6.9) 0.286
Initial WBCa (ml21)
,10 000 80 (48.8) 156 (44.8)
10 000–,50 000 56 (34.1) 111 (31.9)
50 000 16 (9.8) 46 (13.2)
≥100 000 12 (7.3) 35 (10.1) 0.463
Immunophenotype
Pre-B 142 (86.6) 260 (74.7)
Pro-B 5 (3.0) 14 (4.0)
T-cell 17 (10.4) 72 (20.7) 0.011
Other/unknown 0 (0.0) 2 (0.6)
DNA indexb
,1.16 117 (71.3) 208 (59.8)
≥1.16 8 (4.9) 64 (18.4) ,0.001
Unknown 39 (23.8) 76 (21.8)
ETV6/RUNX1
Positive 71 (43.3) 39 (11.2)
Negative 82 (50.0) 283 (81.3) ,0.001
Unknown 11 (6.7) 26 (7.5)
BCR/ABL
Positive 5 (3.0) 8 (2.3)
Negative 158 (96.4) 332 (95.4) 0.765
Unknown 1 (0.6) 8 (2.3)
MLL/AF4
Positive 0 (0.0) 0 (0.0)
Negative 152 (92.7) 320 (92.0) NAe
Unknown 12 (7.3) 28 (8.0)
Prednisone responsec
Good 151 (92.1) 294 (84.5)
Poor 12 (7.3) 52 (14.9) 0.015
Unknown 1 (0.6) 2 (0.6)
Risk group
Standard 61 (37.2) 112 (32.2)
Intermediate 83 (50.6) 169 (48.6)
High 20 (12.2) 67 (19.3) 0.123
aWBC, white blood cell count at diagnosis.
bRatio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes.
cGood:,1000 leukemic blood blasts/ml on treatment Day 8; poor:≥1000 ml21.
dx2- or Fisher’s exact test.
eNA, not applicable.
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largely believed to represent differential effects of sex-specific
hormone action even in prepubertal children (26,27). For the
hematopoietic system, it was demonstrated that 17b-estradiol
treatment can modify the differentiation, proliferation and sur-
vival of early B-cell precursors with a direct influence on Ig
gene rearrangements (28). How these observations could mech-
anistically relate to sex-specific differences in illegitimate
V(D)J-mediated recombination in childhood ALL is currently
only subject to speculation, but it may well be that differences
in endogenous sex hormone exposure could play a modifying
role here. Although sex hormone levels between boys and girls
already differ during infancy, it is of interest that sex bias in
childhood ALL becomes most obvious in children during
puberty when hormonal differences become more profound
(27). That nuclear receptors themselves are implicated in the
mechanism of genomic aberrations was recently demonstrated
by an intriguing observation demonstrating that binding of the
androgen receptor to intronic regions introduces inter- and intra-
chromosomal interactions, leading to double-strand breaks and
ligation by the NHEJ pathway (29). Future mechanistic studies
taking into account this available information may shed some
light on the complex interplay of factors with potential involve-
ment in sex-biased genetic aberrations in childhood ALL.
If the high frequency of the deletion indicates a pathomecha-
nistic role for SLX4IP in ALL leukemogenesis and confers a se-
lective advantage to the affected leukemic clone or simply
reflects an increased locus-specific susceptibility to recombin-
ation events without ‘leukemogenic’ consequences remains
to be evaluated in further detail. Nevertheless, we found that
SLX4IP expression did not differ between leukemic samples carry-
ing the deletion and those not, indicating that loss atSLX4IP seems
to be predominantly monoallelic as demonstrated by array CGH
and does not lead to haploinsufficiency at the transcriptional
level. In contrast, we could demonstrate higher expression of the
SLX4IPneighboring geneJAG1 inSLX4IP-deleted patients. Over-
expression of JAG1—a WNT-dependent Notch signaling activa-
tor with important functions in stem and progenitor cell
homeostasis—has been previously reported in acute myeloid leu-
kemia as well as ETV6/RUNX1-positive ALL (22,23). Since
ETV6—through a consensus sequence on the promoter—may
function as a transcriptional repressor on JAG1, the decrease of
ETV6 activity as a consequence of theETV6/RUNX1 translocation
Table 2. Clinical characteristics of Cohort 1 according to SLX4IP deletion status inETV6/RUNX1-positive and -negative ALL patients treated on AIEOP-BFM ALL
2000
ETV6/RUNX1-positive patients (n ¼ 110) P-valued ETV6/RUNX1-negative patients (n ¼ 365) P-valued
Positive for SLX4IP
deletion (n ¼ 71) n (%)
Negative for SLX4IP
deletion (n ¼ 39) n (%)
Positive for SLX4IP
deletion (n ¼ 82) n (%)
Negative for SLX4IP
deletion (n ¼ 283) n (%)
Gender
Male 47 (66.2) 12 (30.8) 68 (82.9) 154 (54.4)
Female 24 (33.8) 27 (69.2) ,0.001 14 (17.1) 129 (45.6) ,0.001
Age at diagnosis (years)
,1 0 (1.4) 0 (0.0) 0 (0.0) 0 (0.0)
1–,5 42 (59.2) 22 (56.4) 30 (36.6) 126 (44.5)
5–,10 23 (32.4) 14 (35.9) 24 (29.3) 70 (24.7)
10–,15 4 (5.6) 3 (7.7) 19 (23.2) 64 (22.6)
≥15 2 (2.8) 0 (0.0) 0.708 9 (11.0) 23 (8.1) 0.564
Initial WBCa (ml21)
,10 000 40 (56.3) 23(59.0) 36 (43.9) 118 (41.7)
10 000–,50 000 21 (29.6) 9 (23.1) 32 (39.0) 95 (33.6)
50 000 7 (9.9) 6 (15.4) 5 (6.1) 39 (13.8)
≥100 000 3 (4.2) 1 (2.6) 0.738 9 (11.0) 31 (11.0) 0.292
Immunophenotype
Pre-B 70 (98.6) 38 (97.4) 63 (76.8) 202 (71.4)
Pro-B 1 (1.4) 1 (2.6) 4 (4.9) 11 (3.9)
T-cell 0 (0.0) 0 (0.0) NAe 15 (18.3) 68 (24.0) 0.516
Other/unknown 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.7)
DNA indexb
,1.16 49 (69.0) 30 (76.9) 60 (73.2) 167 (59.0)
≥1.16 4 (5.6) 1 (2.6) 0.647 3 (3.6) 57 (20.1) ,0.001
Unknown 18 (25.4) 8 (20.5) 19 (23.2) 59 (20.9)
Prednisone responsec
Good 69 (97.2) 39 (100.0) 73 (89.0) 230 (81.3)
Poor 2 (2.8) 0 (0.0) 0.538 8 (9.6) 52 (18.4) 0.067
Unknown 0 (0.0) 0 (0.0) 1 (1.2) 1 (0.4)
Risk group
Standard 35 (49.3) 28 (71.8) 21 (25.6) 78 (27.6)
Intermediate 34 (47.9) 11 (28.2) 46 (56.1) 142 (50.2)
High 2 (2.8) 0 (0.0) 0.058 15 (18.3) 63 (22.3) 0.609
aWBC, white blood cell count at diagnosis.
bRatio of DNA content of leukemic G0/G1 cells to normal diploid lymphocytes.
cGood: ,1000 leukemic blood blasts/ml on treatment Day 8; poor: ≥1000 ml21.
dx2- or Fisher’s exact test.
eNA, not applicable.
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Table 3. Gender distribution by SLX4IP or TAL1 deletion status in four childhood ALL cohorts from trials AIEOP-BFM ALL 2000 and ALL IC-BFM 2002
Cohort 1a (n ¼ 512)
All patients ETV6/RUNX1-positive (n ¼ 110) ETV6/RUNX1-negative (n ¼ 365)
SLX4IP
deletion-positive
(n ¼ 164) n (%)
SLX4IP
deletion-negative
(n ¼ 348) n (%)
P-valueb SLX4IP
deletion-positive
(n ¼ 71) n (%)
SLX4IP
deletion-negative
(n ¼ 39) n (%)
P-valueb SLX4IP deletion-positive
(n ¼ 82) n (%)
SLX4IP deletion-negative
(n ¼ 283) n (%)
P-valueb
Gender
mc 124 (75.6) 181 (52.0) 47 (66.2) 12 (30.8) 68 (82.9) 154 (54.4)
fc 40 (24.4) 167 (48.0) ,0.001 24 (33.8) 27 (69.2) ,0.001 14 (17.1) 129 (45.6) ,0.001
Cohort 2d (n ¼ 232) Cohort 3e (n ¼ 249) Cohort 4f (n ¼ 1149)
SLX4IP
deletion-positive
(n ¼ 145) n (%)
SLX4IP
deletion-negative
(n ¼ 87) n (%)
P-valueb SLX4IP
deletion-positive
(n ¼ 25) n (%)
SLX4IP
deletion-negative
(n ¼ 224) n (%)
P-valueb TAL1 deletion-positive
T-cell ALL
(n ¼ 128) n (%)
TAL1 deletion-negative
T-cell ALL
(n ¼ 1021) n (%)
P-valueb
Gender
mc 81 (55.9) 37 (42.5) 19 (76.0) 119 (53.1) 110 (85.9) 750 (73.5)
fc 64 (44.1) 50 (57.5) 0.049 6 (24.0) 105 (46.9) 0.029 18 (14.1) 271 (26.5) 0.002
aAnalysis in Cohort 1 included stratification regarding ETV6/RUNX1 translocation and DNA index.
bx2- or Fisher’s exact test.
cm, male; f, female.
dCohort 2 comprised only ETV6/RUNX1 translocation-positive patients.
eCohort 3 comprised only ETV6/RUNX1 translocation-negative patients.
fCohort 4 consisted of 1149 children with T-cell ALL who have been investigated for TAL1 deletions and were recruited from the German ALL-BFM 2000 and additional national trial groups from Austria, Italy,
Czech Republic and Israel.
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was suggested to be responsible for the increase of JAG1 transcrip-
tion in ETV6/RUNX1-positive ALL (23). However, although we
detected differential JAG1 expression by SLX4IP deletion status
in the overall patient group and in theETV6/RUNX1-negative sub-
group, this effect could not be observed in ETV6/RUNX1-positive
patients. This observation contradicts a selective advantage of a
leukemic cell acquiring a SLX4IP deletion by dysregulation of
JAG1 and supports a model where higher regional transcriptional
activity at SLX4IP and the neighboring JAG1 is common toETV6/
RUNX1-rearranged and a subgroup of alike other ALLs which pre-
disposes to SLX4IP deletion through an open chromatin context.
Thus, SLX4IP deletion may act as a surrogate of a local transcrip-
tional profile common toETV6/RUNX1-positive ALL and a group
of ETV6/RUNX1-like ALL with a similarly good prognosis.
In conclusion, the here reported increased susceptibility of
males to illegitimate V(D)J-mediated recombination at SLX4IP
andTAL1may serve as an important etiologicalhint to the current-
ly only poorly understood sex bias in childhood ALL and, at the
same time, may serve the hypothesis of sex-specific differences
in recombination frequencies being associated with higher male
incidences in a majority of hematological neoplasms and their
partly less favorable treatment outcome.
Figure 2. Expression of SLX4IP, MKKS and JAG1 by SLX4IP deletion andETV6/RUNX1 rearrangement status. SLX4IP, MKKS and JAG1 expression in leukemic
bone marrow cells at diagnosis was measured by real-time quantitative polymerase chain reaction after reverse transcription. The horizontal line in each box indicates
the median. The top and bottom of each box indicate the first and third quartiles, respectively, and the tails of the boxes extend to the most extreme values not considered
to be outliers. P-values of the Mann–Whitney U-test are depicted. (A) No difference in SLX4IP expression is observed in SLX4IP deletion-positive and -negative
patients. Patients with ETV6/RUNX1 rearrangement have a slightly higher SLX4IP expression than ETV6/RUNX1-negative patients. (B) MKKS expression is the
same inSLX4IPdeletion positive and negative as well as inETV6/RUNX1 rearrangement-positive and -negative patients. (C) JAG1 expression is depicted in all exam-
ined patients (N ¼ 319). SLX4IP deletion-positive patients as well as ETV6/RUNX1 rearrangement-positive patients have significantly higher JAG1 expression in
comparison to deletion- or rearrangement-negative patients. (D) JAG1 expression after stratification according to ETV6/RUNX1 rearrangement: SLX4IP deletion-
positive ALL samples do express significantly higher JAG1 levels compared with ETV6/RUNX1 rearrangement-negative samples, whereas ETV6/RUNX1
rearrangement-positives all demonstrate high JAG1 expression independent of SLX4IP deletion status. AU, arbitrary units.
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MATERIALS AND METHODS
Study individuals
Patients from Austria, Germany, Italy and Switzerland were en-
rolled in multicenter trial AIEOP-BFM ALL 2000 on treatment
of childhood ALL. Diagnosis, characterization and treatment of
ALL were performed as previously described (see also Supple-
mentary Material) (5,6,30–35).
German patients of AIEOP-BFM ALL 2000 were included for
SLX4IP deletion screening and sequencing, TAL1 deletion ana-
lysis as well as gene expression analysis, Austrian and Italian
patients were only included in TAL1 deletion analysis. Patients
from Czech Republic and Israel were treated in multicenter
trial ALL IC-BFM 2002. Czech patients were included in back-
tracking experiments and subjected to TAL1 deletion analysis,
Israeli patients only employed for TAL1 analysis. German
patients with recurrent ALL were enrolled in relapse trials
ALL-Rez BFM 95/96 and ALL-Rez BFM 2002 and included
in SLX4IP sequencing analyses. Outcome analysis was only per-
formed for German patients treated on AIEOP-BFM ALL 2000.
All trials are described in detail elsewhere and were approved by
the respective institutional review boards (Hannover Medical
School, Hannover; 2nd Faculty of Medicine, Charles University
Prague; Charite´ University Medicine, Berlin) (5,6,36–38).
Informed consent for the use of specimen for research was
obtained from all study individuals, parents or legal guardians.
Samples, cell and DNA isolation
Bone marrow samples were obtained at initial diagnosis, treat-
ment Days 15, 33, 52, 78 and at relapse. Mononuclear cells
were isolated by Ficoll-Paque gradient centrifugation
Figure 2. Continued
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(Pharmacia, Freiburg, Germany) from bone marrow samples
followed by extraction of high-molecular-weight DNA accord-
ing to standardized protocols using either the Puregene DNA iso-
lation system (Gentra Systems, Minneapolis, MN, USA) or
Qiagen DNA Blood Kits (Qiagen, Hilden, Germany). Quality
and quantity of genomic DNA was determined by spectropho-
tometry. DNA yielded from bone marrow aspirates collected
in remission served for germline SLX4IP deletion screening.
An anonymized cohort of blood donors served as healthy
control group.
Comparative genomic hybridization analysis
Nineteen diagnostic DNA samples (blast content .80%) from
GermanAIEOP-BFM ALL 2000patients (Supplementary Mater-
ial, Table S8) who later relapsed and matching remission bone
marrows were hybridized to high-resolution custom-made fine-
tiling CGH arrays covering 62 loci comprising 27 210 197 bp
(Supplementary Material, Table S9). Loci selection was based
on own preliminary experiments employing 100K Affymetrix
arrays (Affymetrix, Santa Clara, CA, USA) and publications
reporting genomic aberrations in ALL (18).
UCSC Human genome build March 2006 (HG18) was used as a
reference. The designed oligonucleotide array comprised 385 000
probes (probe length 50–75mer) and was manufactured, hybri-
dized and scanned by imaGenes GmbH (NimbleGen service:
ROCHE NimbleGen, Reykjavik, Iceland). Repeat regions were
excluded and oligonucleotide spacing was ,71 bp on average
(SupplementaryMaterial,TableS9).DatawereanalyzedusingSig-
nalMap Version 1.9.0.03 (NimbleGen Systems, Inc., Madison, WI,
USA).
SLX4IP and TAL1 deletion screening and genomic
sequencing, MLPA
SLX4IP deletion breakpoints were amplified by genomic PCR
using primers (5′  3′) forward: gataattcacccggcatttccccatc
and reverse: atgcccccgaggcctctctacaaact (39). Product length
was 705 bp when SLX4IP deletion was present; sequencing
primers (5′  3′) were forward: tgttcaaacatggctatttttatt and
reverse: cctgtctatgagactgccaaa. For TAL1 deletion analysis,
diagnostic leukemic DNA samples were screened using the
BIOMED-1 primer set (40).
Amplification of SLX4IP deletion breakpoints was performed
by genomic PCR (forward primer (5′ –3′): gataattcacccgg-
catttccccatc and reverse primer (5′ –3′): atgcccccgaggcctctcta-
caaact) (39). Fifty nanograms of leukemic blast DNA or
human control DNA were amplified using the Qiagen Mutation
Detect PCR Kit (Qiagen). As a positive control, a fragment
encompassing HPRT exons 7 and 8 was amplified using the fol-
lowing primers: forward (5′ –3′): gtaatattttgtaattaacagcttgctgg
and reverse (5′ –3′): tcagtctggtcaaatgacgaggtgc (product length
423 bp). PCR conditions were: 958C for 5 min followed by
35 cycles of 958C for 30 s and 618C for 1 min and 728C for
3 min. PCR products were analyzed on a multicapillary electro-
phoresis system (QIAxcel, Qiagen). Before direct sequencing,
PCR products were run on a 1.0% agarose gel and purified
using the Qiagen gel extraction Kit (Qiagen). Product length
was 705 bp when SLX4IP deletion was present. The nucleo-
tide sequences of both strands of the PCR products were directly
determined using an automated fluorescent sequencer (ABI
Prism 310 Genetic Analyzer, Perkin Elmer Corporation, Welles-
ley, MA, USA). Primer sequences used for sequencing were the
following: forward (5′ –3′): tgttcaaacatggctatttttatt and reverse
(5′ –3′): cctgtctatgagactgccaaa. When distinct breakpoints with
non-ambiguous sequencing results continuing behind the break-
point junction in forward and reverse sequencing reactions were
observed, monoclonality of SLX4IP deletion was assumed
(Fig. 1C). In the case of non-ambiguous sequencing results
before the breakpoint junction (in forward and reverse reactions)
with sudden indistinct sequencing signature or with one major-
sequence as well as another upcoming minor sequence signature
behind the typicalbreakpoint junction,oligoclonalitywashypothe-
sized (Supplementary Material, Tables S3 and S4 and Fig. S3). In
these cases, true breakpoints might deviate by 1–2 nucleotides
from those depicted in Supplementary Material, Tables S5 and
S6, due to ambiguous breakpoint junction assignment.
Primer design in the BIOMED-1 approach for the TAL1 dele-
tion was restricted to the breakpoint in the SIL gene and the two
most frequent breakpoints in the TAL1 gene, type 1 and type 2
(taldb1 and taldb2), covering at least 95% of all known TAL1
deletions. PCR products obtained were further examined by het-
eroduplex or gene scanning analyses to discriminate between
amplifications derived from monoclonal or polyclonal lympho-
blastic cell populations and junctional regions of clonal PCR
products were sequenced.
MLPA was performed as described previously (25).
Deletion backtracking in Guthrie cards and ETV6/RUNX1
genomic breakpoint cloning
For backtracking of SLX4IP deletions to the time of birth,
genomic DNA from Guthrie cards was isolated using the Insta-
Gene Dry Blood Kit (Bio-Rad, Hercules, CA, USA). Three sep-
arate sections (1/8) of one Guthrie card were used in PCR
reactions. For SLX4IP deletion screening, specific primers
were designed. The amplified products were analyzed by auto-
mated chip-based microcapillary electrophoresis on an Agilent
2100 Bioanalyzer instrument (Agilent Technologies, Santa
Clara, CA, USA). Assay specificity was determined using
serial dilutions of individual diagnostic DNA in healthy donor
DNA. Guthrie card PCRs were performed in a separate room
in a separate PCR box. For SLX4IP deletion screening in
Guthrie cards specific primers were designed: forward (5′ –3′):
agaaaacacaccacagaaaagc and reverse (5′ –3′): gggaggtgaggagc-
cactat. PCR conditions were: initial denaturation at 958C for
10 min; 35 cycles at 948C for 30 s, 58.58C for 30 s, 728C for
30 s, final extension 728C for 7 min. ETV6/RUNX1 genomic
breakpoints in monozygotic twins were cloned as described pre-
viously (41).
RNA isolation, reverse transcription and gene expression
analysis by real-time quantitative PCR
Total RNA was isolated with Triazol reagent (Invitrogen, Paisley,
UK) and subsequently passed over a Qiagen RNeasy column
(Qiagen) for removal of small fragments. Total RNA was quanti-
fied and validated for integrity using the Bioanalyzer 2100
(Agilent, Palo Alto, CA, USA). Real-time quantitative polymer-
ase chain reaction (RQ-PCR) analysis was performed after
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random hexamer priming and MuLV reverse transcription (Fer-
mentas, Hanover, MD, USA) to generate cDNA. PCR was
carried out on an Applied Biosystems Model 7900 HT Sequence
Detector (Darmstadt, Germany) using the QuantiTect SYBR
Green PCR kit (Qiagen) as described in the manufacturer’s
instructions. The expression level of the SDHA and ABL1 were
used to normalize for differences in input cDNA. QuantiTect
Primer Assays were used to measure mRNA abundances of the
SLX4IP, MKKS and JAG1 genes (Qiagen). Melting curve ana-
lyses were performed to verify the amplification specificity.
Each sample was tested in duplicate. The expression ratio was cal-
culated as 2n, where n was the threshold cycle (CT) value differ-
ence normalized by the CT difference of a calibrator sample.
For SLX4IP and MKKS expression analysis 120 German
patients from trial AIEOP-BFM ALL 2000 with known SLX4IP
deletion status and RNA availability were selected. Selection cri-
teria were as following: half of the 120 patient samples were either
SLX4IP deletion-negative (n ¼ 60) or positive (n ¼ 60). Within
each of the two subgroups, half of the patients were ETV6/
RUNX1 translocation-negative (n ¼ 30) or positive (n ¼ 30). Ex-
clusion criteria comprised: BCR/ABL1 or MLL rearrangement,
T-ALL and hyperdiploidy (Supplementary Material, Table S5).
For JAG1 expression analysis, 319 German patients from trial
AIEOP-BFM ALL 2000 with known SLX4IP deletion status
and RNA availability were selected (Supplementary Material,
Table S6).
Statistical analysis
Differences in the distribution of categorical variables among
patient subsets were analyzed using Fisher’s exact or x2-test.
Comparisons of gene expression levels between groups were
performed by Mann–Whitney U-test. Event-free survival was
defined as the time from diagnosis to the date of last follow-up
in complete remission or to the first event. Events were resistance
to therapy (non-response), relapse, secondary neoplasm or death
from any cause. Failure to achieve remission due to early death or
non-response was considered as event at time zero. Patients lost
to follow-up were censored at the time of their withdrawal. The
Kaplan–Meier method was used to estimate survival rates, differ-
ences werecomparedwith the two-sided log-ranktest (42,43).Cu-
mulative incidence functions for competing events were
constructed by the method of Kalbfleisch and Prentice, and
were compared employing the Gray’s test (44,45). Computations
were performed using SPSS Version 17.0 (SPSS, Armonk, NY,
USA) and SAS Version 9.1 (SAS, Cary, NC, USA) statistical
programs.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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